Canine Urolithiasis: Medical Dissolution and Prevention

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Medical dissolution of canine uroliths is feasible for struvite, urate, and cystine types, contingent on accurate mineral identification, absence of obstruction, and owner compliance; calcium oxalate uroliths are not amenable to dissolution and require surgical removal or prevention strategies.
• Infection-induced struvite uroliths necessitate concurrent antimicrobial therapy guided by urine culture and susceptibility testing, alongside a calculolytic diet to lower urine pH below 6.5 and reduce substrate availability.
• Urate urolith dissolution requires a low-purine, alkalinizing diet to achieve a urine pH of 7.0-7.5, with xanthine oxidase inhibitors considered for persistent hyperuricosuria, particularly in breeds with metabolic defects or portosystemic shunts.
• Cystine urolith management involves increasing urine volume, alkalinizing urine to a pH of 7.0-7.5, and restricting dietary protein, with thiol-binding agents like tiopronin used as adjuncts in refractory cases.
• Prevention of calcium oxalate urolith recurrence focuses on increasing urine volume, moderate protein intake, sodium restriction, low dietary oxalate, and adequate dietary calcium, often supplemented with potassium citrate to increase urinary citrate levels.
• Consistent monitoring, including serial imaging (radiography/ultrasonography), urine pH measurement, and urine culture, is critical for assessing dissolution progress, detecting complications like urethral obstruction, and guiding long-term prevention strategies.

Medical dissolution and prevention of canine uroliths require identification of the mineral composition, correction of the underlying metabolic or infectious disorder, and sustained modification of urine composition to achieve undersaturation. This article provides a decision-oriented reference for practicing veterinarians managing dogs with urolithiasis, with emphasis on struvite, urate, cystine, and calcium oxalate uroliths. It addresses patient selection for medical protocols, dietary and pharmacologic interventions, monitoring parameters, and common reasons for treatment failure. Surgical removal and diagnostic imaging are outside the scope of this article.

The clinical question this article answers is straightforward: which dogs are candidates for medical dissolution, what protocol should be implemented for each urolith type, and how should prevention be tailored once dissolution is achieved or after surgical removal? The principles follow from the pathophysiology of urolith formation, which is summarized first, followed by mineral-specific protocols.

At a Glance

Pathophysiology of Urolith Formation

Urolithiasis is a complication of one or more underlying disorders instead of a primary disease. Formation requires urine that is oversaturated with the mineral precursors of the urolith, a condition that permits crystal nucleation, growth, and aggregation. The objectives of medical management are to arrest further growth and promote dissolution by correcting or controlling these underlying abnormalities. Effective therapy must promote undersaturation of urine with lithogenic crystalloids by increasing the urine solubility of crystalloids, increasing urine volume, and reducing the quantities of lithogenic crystalloids in urine, as summarized in the Minnesota Urolith Center's review of nutritional management of urolithiasis.

Urine pH is a dominant determinant of solubility for struvite, urate, and cystine, but it is a less reliable lever for calcium oxalate. Urine volume dilutes all crystalloids and is therefore universally beneficial. Infection with urease-producing bacteria, most commonly staphylococci, raises urine pH and provides ammonia, directly driving struvite precipitation. Inherited or acquired metabolic defects, such as cystinuria or hyperuricosuria, create persistent oversaturation independent of diet. Identifying which factors are operative in an individual dog determines whether medical dissolution is feasible and which protocol is appropriate.

Patient Selection for Medical Dissolution

Medical dissolution is appropriate only when the urolith is composed of a mineral that can be dissolved, the urinary tract is not obstructed, and the owner can adhere to a strict protocol. Surgery is indicated for patients with obstructive uropathy, for uroliths refractory to medical dissolution, and for calcium oxalate, calcium phosphate, and silica uroliths, which are not amenable to dissolution, as described in the surgical indications review by Caywood and Osborne. Cystine uroliths may be considered for medical dissolution, but surgery is an acceptable alternative if dissolution is unlikely or adherence is questionable.

Before initiating any dissolution protocol, urolith composition must be established. If a urolith has been passed or removed, quantitative analysis should be performed. If no urolith is available, urine sediment examination for characteriztic crystals, urine culture, and breed-specific genetic testing can provide supportive evidence, but these are not definitive. Imaging is used to document urolith size and number at baseline and to monitor dissolution, although detailed imaging protocols are outside the scope of this article. Dogs with uroliths that have not changed in size over several months, or that are increasing despite appropriate medical therapy, should be reevaluated for incorrect mineral identification or nonadherence.

Struvite Uroliths

Infection-Induced Struvite

Infection-induced struvite is the most common type of canine struvite urolith, and it is almost always associated with urease-producing staphylococcal urinary tract infection. Sterile struvite uroliths are recognized but uncommon. For dogs that qualify, medical dissolution is an effective treatment. The protocol encompasses three components: eradication or control of urinary tract infection, use of a calculolytic diet, and administration of urease inhibitors to patients with persistent infection caused by urease-producing microbes, as detailed in the twenty-year experience with medical dissolution of canine struvite urolithiasis.

Antimicrobial therapy must be selected on the basis of urine culture and susceptibility testing. The infection must be eliminated or suppressed for the duration of dissolution. The calculolytic diet is restricted in protein, magnesium, and phosphorus and is formulated to maintain urine pH below 6.5. This diet reduces the substrates available for struvite precipitation and acidifies the urine, increasing struvite solubility. In the feline model, sterile struvite urocystoliths dissolved in a mean of 36 days, and struvite uroliths associated with urease-negative bacterial infection dissolved in a mean of 23 days, whereas struvite uroliths associated with urease-positive staphylococcal infection took a mean of 79 days, as reported in the study of medical dissolution of feline struvite urocystoliths. Canine dissolution times are generally comparable, though they vary with urolith size, infection status, and adherence.

Urease inhibitors, such as aceturonide or its analogues, reduce urine ammonia production and are reserved for dogs with persistent urease-positive infection that cannot be eradicated. These agents are adjunctive, not primary therapy, and current formulary references must be consulted for dosing and adverse effect profiles.

Sterile Struvite

Sterile struvite uroliths are uncommon in dogs. They occur in the absence of urease-producing infection and are managed with the same calculolytic diet used for infection-induced struvite, without antimicrobials unless a concurrent non-urease infection is present. Dissolution is typically faster than for infection-induced struvite because the driving force, urease-mediated ammonia production, is absent.

Urate Uroliths

Urate uroliths form when urine is oversaturated with uric acid, most commonly because of hyperuricosuria. In dogs, hyperuricosuria is often associated with a congenital portosystemic shunt or with a breed-related defect in uric acid metabolism, such as that seen in Dalmatians. Dogs with portosystemic shunts also have reduced hepatic conversion of uric acid to allantoin and may have concurrent ammonium urate precipitation. Medical dissolution of urate uroliths is feasible in many dogs, but the underlying cause must be identified. A dog with a portosystemic shunt may require surgical attenuation before dissolution can succeed, and the ACVIM consensus statements provide guidance on the diagnostic evaluation of hepatic function in this setting.

The dissolution diet for urate uroliths is low in purines, which reduces uric acid precursors, and is formulated to alkalinize urine to a pH of 7.0 to 7.5, increasing uric acid solubility. Urine volume is increased through dietary moisture content and, if necessary, additional water intake. Xanthine oxidase inhibitors reduce uric acid production and may be used as an adjunct in dogs with persistent hyperuricosuria, particularly those with breed-related defects. These agents are not a substitute for dietary modification and should be used only when dietary therapy alone is insufficient. Monitoring includes serial imaging, urine pH measurement, and assessment of urine uric acid concentration where available.

Cystine Uroliths

Cystine uroliths form in dogs with cystinuria, an inherited defect in renal and intestinal transport of cystine and the dibasic amino acids ornithine, lysine, and arginine. At normal urine pH, cystine is relatively insoluble, and precipitation occurs when urine becomes supersaturated. The prevalence of cystine urolithiasis is higher in European countries, where it may account for up to 14% of canine uroliths, compared with approximately 1% to 3% in North America cystinuria in dogs and cats review.

Diagnosis and Metabolic Confirmation

Cystine uroliths are suspected when hexagonal crystals appear in urine sediment, but crystalluria is not consistently present. Definitive diagnosis requires stone analysis after retrieval or, when uroliths cannot be collected, quantitative amino acid chromatography of urine. Genetic testing is available for some breeds with known mutations, but a negative genetic test does not exclude cystinuria because mutations have been identified in only some breeds cystinuria in dogs and cats review.

Dissolution Protocol

Medical dissolution of cystine uroliths is feasible in many dogs, though success rates are lower than for struvite. The protocol has three components.

First, increase urine volume. Canned diets and added water reduce urine specific gravity and lower cystine concentration. Second, alkalinize the urine. Cystine solubility increases markedly as urine pH rises above 7.0. A target urine pH of 7.0 to 7.5 is generally recommended, measured on fresh urine samples collected at home to avoid the effects of hospital stress and delayed analysis. Third, restrict dietary protein. Low-protein diets reduce the filtered load of cystine precursors. A diet formulated for renal support or a dedicated calculolytic diet is appropriate.

When dietary management alone is insufficient, medical therapy with a thiol-containing agent such as tiopronin (2-mercaptopropionylglycine) may be added. These agents reduce cystine to a more soluble form. Current formulary and label references must be consulted for dosing, monitoring, and adverse effect profiles.

Monitoring and Failure Modes

Radiographic or ultrasonographic monitoring every 4 to 8 weeks is appropriate during dissolution attempts. Cystine uroliths are radiopaque, which permits radiographic tracking of size. If urolith size does not decrease within 8 to 12 weeks, reassess owner compliance, urine pH, and urine specific gravity. Persistent acidic urine is the most common reason for failure. Concurrent urinary tract infection must be excluded because infection alters urine pH and complicates dissolution.

Castration is recommended in intact male dogs with cystine urolithiasis because androgen-dependent cystinuria has been documented in some breeds cystinuria in dogs and cats review. Castration does not eliminate cystinuria but may reduce cystine excretion in affected dogs.

Prevention

Prevention of recurrence follows the same principles as dissolution: high water intake, dietary protein restriction, and urine alkalinization. Long-term monitoring should include urine pH measured at home, periodic urinalysis for crystalluria, and imaging at 3 to 6 month intervals during the first year, then at 6 to 12 month intervals thereafter. Dogs that required pharmacologic therapy for dissolution may need continued therapy for prevention, with dose adjustments based on urine cystine quantification.

Calcium Oxalate Uroliths

Calcium oxalate uroliths are not amenable to medical dissolution. Surgical or minimally invasive removal is required when uroliths must be treated calcium oxalate urolithiasis risk factors and treatment. Medical management therefore focuses exclusively on prevention of recurrence.

Risk Factor Identification

Prevention begins with identification of modifiable risk factors. Hypercalciuria, hyperoxaluria, hypocitraturia, and low urine volume all contribute to calcium oxalate supersaturation. Underlying disorders that cause hypercalcemia, such as primary hyperparathyroidism, must be excluded with serum biochemistry, including ionized calcium. Urine culture is indicated because urinary tract infection can alter urine composition and promote crystal formation.

Dietary Prevention

Dietary prevention targets reduced urine saturation with calcium oxalate. The objectives are to increase urine volume, reduce urinary excretion of calcium and oxalate, and increase urinary concentrations of inhibitors such as citrate nutritional management of urolithiasis.

A prevention diet should be canned or moistened to maximize water intake. Dietary protein should be moderate, not severely restricted, because protein restriction alone does not reliably reduce calcium oxalate risk. Sodium restriction is appropriate because high sodium intake increases urinary calcium excretion. Oxalate content of the diet should be low. Calcium should not be severely restricted because dietary calcium binds oxalate in the intestinal lumen and reduces oxalate absorption. Most commercial calcium oxalate prevention diets are formulated with these principles in mind.

Pharmacologic Adjuncts

Potassium citrate is the most commonly used adjunct. It provides an alkali load that increases urinary citrate excretion, and citrate complexes calcium, reducing free calcium ion activity. Urine pH should be monitored because excessive alkalinization increases the risk of calcium phosphate urolith formation. A target urine pH of 6.5 to 7.0 is generally appropriate.

Thiazide diuretics reduce urinary calcium excretion and may be considered in dogs with documented hypercalciuria that persists despite dietary modification. Monitoring includes serum biochemistry, urine specific gravity, and urine pH. Current formulary references must be consulted for dosing and adverse effect profiles.

Monitoring and Recurrence Assessment

Recurrence of calcium oxalate uroliths is common. Imaging at 3 to 6 month intervals during the first year after urolith removal is recommended, with intervals extended if no recurrence is documented. Urinalysis should assess crystalluria, urine pH, and urine specific gravity. Quantitative urine calcium and oxalate measurements, where available, can guide therapy adjustments.

Monitoring Protocols Across Urolith Types

When Medical Management Is Not Appropriate

Medical dissolution is contraindicated in several situations. Complete urethral obstruction requires immediate intervention. Uroliths refractory to an appropriate dissolution trial should be removed surgically surgical removal of canine uroliths. Nephroliths associated with progressive renal dysfunction warrant surgical evaluation. Anatomic defects that predispose to urinary tract infection, such as urachal remnants or vaginal strictures, should be corrected because persistent infection will defeat dissolution efforts surgical removal of canine uroliths.

Patient temperament and owner compliance determine whether medical dissolution is feasible. Dissolution requires strict dietary adherence, frequent urine pH monitoring, and repeated imaging. Owners who cannot commit to this protocol should be offered surgical removal as the primary treatment.

Documentation and Case Tracking

Each patient should have a written plan that records urolith composition, baseline imaging findings, urine pH and specific gravity, culture results, and the specific dissolution or prevention protocol selected. Follow-up visits should document urine pH trends, body weight, and imaging measurements. Serial imaging should use consistent positioning and technique so that size comparisons are meaningful. When uroliths are retrieved, submit them for quantitative analysis. This documentation supports treatment adjustments and provides the data needed to counsel owners about recurrence risk.

Recognized Complications and Early Detection

Medical dissolution fails or causes harm when monitoring is delayed or misinterpreted. The most serious complication is undetected urethral obstruction during dissolution. Calculi that fragment can lodge in the urethra, particularly in male dogs. Owners must be instructed to observe urination frequency and stream daily, and any sign of stranguria or anuria warrants immediate re-evaluation.

Urinary tract infection during dissolution is a second major concern. Infection-induced struvite dissolution requires concurrent antimicrobial therapy, and urine culture should be repeated 5 to 7 days after starting treatment and again at each recheck Medical dissolution and prevention of canine struvite urolithiasis. Twenty. Persistent infection with a urease-producing organizm prolongs dissolution and can enlarge calculi despite dietary therapy.

Dietary intolerance is common. Calculolytic diets are often high in sodium and low in protein, and some dogs develop vomiting, diarrhea, or reduced appetite. Serial body weight measurement at each recheck detects early muscle loss. Refusal to eat for more than 48 hours warrants transition to an alternative calculolytic product or reassessment of whether dissolution remains appropriate.

Hyperchloraemic metabolic acidosis can develop with prolonged feeding of acidifying diets. Suspect this when dogs show lethargy, tachypnoea, or poor appetite. Venous blood gas analysis and urine pH measurement distinguish diet-induced acidosis from unrelated disease.

Common Errors and Corrective Actions

The most frequent error is attempting dissolution without mineral confirmation. Struvite and cystine can sometimes be dissolved, but calcium oxalate and silica cannot Surgical removal of canine uroliths. A dog with calcium oxalate uroliths fed a struvite dissolution diet will not improve and may develop worsening hypercalciuria. Always confirm composition by stone analysis, or by crystalluria and urine pH patterns when analysis is unavailable.

A second error is failing to treat infection-induced struvite with antimicrobials selected by culture. Empirical antibiotic choice risks resistance and prolongs dissolution. Repeat culture at each recheck because sterilization of urine is required for dissolution to proceed Medical dissolution and prevention of canine struvite urolithiasis. Twenty.

A third error is discharging the dog without a written monitoring schedule. Dissolution requires recheck imaging at defined intervals, typically every 4 weeks for struvite and every 4 to 8 weeks for cystine and urate. Without scheduled rechecks, failure is detected late and the dog may develop obstruction or progressive nephrolithiasis.

Less experienced clinicians sometimes continue dissolution beyond 12 weeks without imaging. If no reduction in stone size or number is seen by 8 to 12 weeks, the diagnosis, diet, and infection status must be reassessed. Continuing the same protocol is not appropriate.

Limitations of Current Evidence

The evidence base for canine dissolution is strongest for infection-induced struvite, where clinical studies spanning two decades support dietary and antimicrobial protocols Medical dissolution and prevention of canine struvite urolithiasis. Twenty. Sterile struvite dissolution is documented but uncommon, and the distinction between sterile and infection-induced disease can blur when low-grade urease-producing infections are missed.

Cystine dissolution evidence is largely extrapolated from clinical experience instead of controlled trials. The genetic basis of cystinuria is breed-specific and incompletely characterized, and response to dietary therapy varies with the underlying transporter defect Cystinuria in Dogs and Cats: What Do We Know. Some dogs require thiol-containing drugs, but these carry hepatotoxicity risk and are not universally effective.

Urate dissolution is well supported in dogs with portovascular anomalies, but evidence is thinner for dogs with idiopathic hyperuricosuria. Expert opinion differs on the role of allopurinol versus dietary management alone, and on the target urine pH for maximal urate solubility Paradigm changes in the role of nutrition for the.

Calcium oxalate prevention relies on reducing urine supersaturation, but the relative importance of urine volume, calcium, oxalate, and citrate remains debated Feline Calcium Oxalate Urolithiasis: Risk factors and rational treatment. No diet reliably prevents recurrence in all dogs, and individual metabolic profiling is often needed.

Referral and Escalation Criteria

Referral to a specialist is warranted when dissolution fails despite confirmed mineral type and compliance, when nephroliths are present with progressive azotaemia, or when recurrent urethral obstruction occurs during therapy Surgical removal of canine uroliths. Dogs with suspected portovascular anomalies and urate uroliths benefit from advanced imaging and surgical or interventional planning before dissolution is attempted.

Laboratory involvement is indicated for stone analysis, urine culture, and genetic testing for cystinuria where breed-specific mutations are known Cystinuria in Dogs and Cats: What Do We Know. Consultation with a veterinary nutritionist is appropriate when dietary intolerance limits therapy or when comorbidities such as chronic kidney disease complicate protein restriction.

Regulatory reporting is rarely required for urolithiasis itself. However, if a commercial diet is suspected of causing adverse effects, reporting to the manufacturer and to the relevant national pharmacovigilance or feed safety authority is appropriate. Practitioners should follow the reporting pathways described in professional guidance from bodies such as the AVMA practice resources and, where relevant, international standards for veterinary products WOAH terrestrial animal health standards.

Frequently Asked Questions

How should I adjust my dissolution plan when a client cannot afford a commercial calculolytic diet?

When cost limits access to a commercial dissolution diet, medical dissolution becomes less predictable. The diet is the primary driver of urine undersaturation, so substituting a homemade or maintenance ration is not an evidence-based alternative. Discuss the expected duration and total cost of dietary therapy, including serial urinalyses and imaging, against the cost of surgical removal. If the client cannot commit to the full protocol, referral for minimally invasive removal may be more economical and safer than a partial medical attempt. Document the financial discussion and the client's informed choice. The objectives of medical management, including promoting urine undersaturation, cannot be met reliably without the prescribed diet (Minnesota Urolith Center research summary).

What do I do when urine culture or imaging is unavailable in my practice setting?

Without urine culture, you cannot distinguish infection-induced from sterile struvite uroliths, and empirical antimicrobial choice is unreliable. If culture is unavailable, collect urine aseptically and submit to a reference laboratory before starting dissolution. Imaging confirmation of urolith size and location is required before medical dissolution, because a urethral or ureteral stone may obstruct during therapy. If radiography or ultrasonography is unavailable, refer for imaging before initiating treatment. Medical dissolution of struvite uroliths requires confirmation of the mineral type, which is inferred from imaging, urine pH, and crystalluria when stone analysis is not possible (ACVIM consensus statements).

How does the dissolution approach differ in cats compared with dogs?

Feline struvite uroliths are usually sterile and dissolve more rapidly than canine infection-induced stones. In one institutional series, sterile feline struvite urocystoliths dissolved in a mean of 36 days, and those associated with urease-negative infection dissolved in a mean of 23 days, whereas urease-positive staphylococcal infections required a mean of 79 days (feline struvite dissolution study). Canine struvite dissolution is slower because infection-induced stones are more common and require concurrent antimicrobial therapy. Feline calcium oxalate uroliths are not amenable to dissolution, and prevention focuses on reducing urine saturation (feline calcium oxalate risk factors). Cystinuria is less frequent in cats than in dogs, and breed-specific genetic testing is less established in cats (cystinuria review).

What records should I maintain for a patient undergoing urolith dissolution?

Maintain a dated log that includes urolith dimensions from each imaging study, urine pH, urine specific gravity, sediment findings, culture results, antimicrobial selection, diet name and start date, and body weight. Record the calculated dissolution timeline and any deviation from it. Document client communications about diet compliance, medication administration, and recheck scheduling. Serial imaging measurements must be compared directly, using the same modality and ideally the same observer, to detect growth or stagnation. If a urolith fails to decrease in size within the expected interval, the record should show the decision point for reassessment or referral. This documentation supports both clinical decisions and client communication (MSD Veterinary Manual).

How should I explain medical dissolution to a client who expects immediate stone passage?

Explain that dissolution works gradually by changing urine composition so the stone dissolves from the outside inward, not by flushing it out. Provide a realistic timeline based on stone type and infection status, and warn that the stone may appear unchanged on radiographs for several weeks before measurable size reduction occurs. Emphasize that the diet is therapeutic, not maintenance, and that treats or table food will undermine the protocol. Instruct the client to monitor for stranguria, hematuria, or urethral obstruction, particularly in male dogs, and to seek immediate care if these signs appear. The goal of therapy is to promote urine undersaturation with lithogenic crystalloids, which requires strict dietary adherence (Minnesota Urolith Center research summary).

When should I stop medical dissolution and refer for surgical removal?

Discontinue medical dissolution and refer when a urolith increases in size despite appropriate therapy, when no reduction is seen after the expected dissolution interval, or when urethral obstruction develops. Surgery is also indicated for calcium oxalate, calcium phosphate, and silica uroliths, which are not amenable to dissolution, and for uroliths refractory to medical management (surgical indications review). Refer early if the patient has concurrent nephrolithiasis with progressive renal dysfunction or an anatomic defect predisposing to infection. Persistent urease-positive infection despite appropriate antimicrobial therapy is another indication for surgical removal, because ongoing infection will continue to generate struvite.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Medical dissolution of feline struvite urocystoliths.. 1990.
• Feline Calcium Oxalate Urolithiasis: Risk factors and rational treatment approaches.. 2016.
• Cystinuria in Dogs and Cats: What Do We Know after Almost 200 Years?. 2021.
• Surgical removal of canine uroliths.. 1986.
• Medical dissolution and prevention of canine struvite urolithiasis. Twenty years of experience.. 1999.
• Paradigm changes in the role of nutrition for the management of canine and feline urolithiasis.. 2009.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Portosystemic Shunt: Medical and Surgical Management
• Canine Intervertebral Disc Disease: Medical and Surgical Management
• Canine Hypoadrenocorticism: Diagnostic and Therapeutic Monitoring
• Canine Proteinuria: Diagnostic Approach and Management
• Canine Endocrine Testing: Interpretation and Diagnostic Strategy

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.